An alternative splicing isoform of eukaryotic initiation factor 4H promotes tumorigenesis in vivo and is a potential therapeutic target for human cancer

International Journal of Cancer

Volumn 128, Issue 5, 2011, Pages 1018-1030

  Wu, Di ^a,b   Matsushita, Kazuyuki ^a   Matsubara, Hisahiro ^a   Nomura, Fumio ^a   Tomonaga, Takeshi ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

alternative splicing; therapeutic target; translation initiation factor

Indexed keywords

CYCLIN D1; INITIATION FACTOR; INITIATION FACTOR 4H; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; FIBROBLAST; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

AGED; ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; ESOPHAGEAL NEOPLASMS; EUKARYOTIC INITIATION FACTORS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NIH 3T3 CELLS; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS; RNA, SMALL INTERFERING;

EID: 78650745895     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25419     Document Type: Article

References (38)

1. Averous J, Proud CG,. When translation meets transformation: the mTOR story. Oncogene 2006; 25: 6423-35.
2. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N,. eIF4E-from translation to transformation. Oncogene 2004; 23: 3172-9.
3. Clemens MJ,. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004; 23: 3180-8.
4. de Benedetti A, Graff JR,. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23: 3189-99.
5. Rosenwald IB,. The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene 2004; 23: 3230-47.
6. Lazaris-Karatzas A, Montine KS, Sonenberg N,. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5â-cap. Nature 1990; 345: 544-7.
7. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP,. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10: 484-6.
8. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, Polunovsky VA,. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004; 5: 553-63.
9. Brass N, Heckel D, Sahin U, Pfreundschuh M, Sybrecht GW, Meese E,. Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum Mol Genet 1997; 6: 33-9.
10. Bauer C, Diesinger I, Brass N, Steinhart H, Iro H, Meese EU,. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer 2001; 92: 822-9.
11. Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H, Igarashi K,. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res 1997; 57: 5041-4.
12. Eberle J, Krasagakis K, Orfanos CE,. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int J Cancer 1997; 71: 396-401.
13. Shuda M, Kondoh N, Tanaka K, Ryo A, Wakatsuki T, Hada A, Goseki N, Igari T, Hatsuse K, Aihara T, Horiuchi S, Shichita M, et al. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Res 2000; 20: 2489-94.
14. Rogers GW, Jr, Richter NJ, Merrick WC,. Biochemical and kinetic characterization of the RNA helicase activity of eukaryotic initiation factor 4A. J Biol Chem 1999; 274: 12236-44.
15. Richter-Cook NJ, Dever TE, Hensold JO, Merrick WC,. Purification and characterization of a new eukaryotic protein translation factor. Eukaryotic initiation factor 4H. J Biol Chem 1998; 273: 7579-87.
16. Richter NJ, Rogers GW, Jr, Hensold JO, Merrick WC,. Further biochemical and kinetic characterization of human eukaryotic initiation factor 4H. J Biol Chem 1999; 274: 35415-24.
17. Tomonaga T, Matsushita K, Yamaguchi S, Oh-Ishi M, Kodera Y, Maeda T, Shimada H, Ochiai T, Nomura F,. Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin Cancer Res 2004; 10: 2007-14.
18. Black DL,. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003; 72: 291-336.
19. Brinkman BM,. Splice variants as cancer biomarkers. Clin Biochem 2004; 37: 584-94.
20. Srebrow A, Kornblihtt AR,. The connection between splicing and cancer. J Cell Sci 2006; 119: 2635-41.
21. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM,. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007; 8: 349-57.
22. Martindale DW, Wilson MD, Wang D, Burke RD, Chen X, Duronio V, Koop BF,. Comparative genomic sequence analysis of the Williams syndrome region (LIMK1-RFC2) of human chromosome 7q11.23. Mamm Genome 2000; 11: 890-8.
23. Tomonaga T, Matsushita K, Yamaguchi S, Oohashi T, Shimada H, Ochiai T, Yoda K, Nomura F,. Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. Cancer Res 2003; 63: 3511-6.
24. Tomonaga T, Matsushita K, Ishibashi M, Nezu M, Shimada H, Ochiai T, Yoda K, Nomura F,. Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy. Cancer Res 2005; 65: 4683-9.
25. Rousseau D, Kaspar R, Rosenwald I, Gehrke L, Sonenberg N,. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci USA 1996; 93: 1065-70.
26. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL,. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J 2001; 20: 4547-59.
27. Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, Borden KL,. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol 2003; 23: 8992-9002.
28. Clemens MJ, Bushell M, Morley SJ,. Degradation of eukaryotic polypeptide chain initiation factor (eIF) 4G in response to induction of apoptosis in human lymphoma cell lines. Oncogene 1998; 17: 2921-31.
29. Hayashi S, Nishimura K, Fukuchi-Shimogori T, Kashiwagi K, Igarashi K,. Increase in cap- and IRES-dependent protein synthesis by overproduction of translation initiation factor eIF4G. Biochem Biophys Res Commun 2000; 277: 117-23.
30. Kevil C, Carter P, Hu B, DeBenedetti A,. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene 1995; 11: 2339-48.
31. Scott PA, Smith K, Poulsom R, de Benedetti A, Bicknell R, Harris AL,. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 1998; 77: 2120-8.
32. Shantz LM, Pegg AE,. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res 1994; 54: 2313-6.
33. Clemens MJ, Bushell M, Jeffrey IW, Pain VM, Morley SJ,. Translation initiation factor modifications and the regulation of protein synthesis in apoptotic cells. Cell Death Differ 2000; 7: 603-15.
34. Morley SJ, Jeffrey I, Bushell M, Pain VM, Clemens MJ,. Differential requirements for caspase-8 activity in the mechanism of phosphorylation of eIF2alpha, cleavage of eIF4GI and signaling events associated with the inhibition of protein synthesis in apoptotic Jurkat T cells. FEBS Lett 2000; 477: 229-36.
35. Li S, Takasu T, Perlman DM, Peterson MS, Burrichter D, Avdulov S, Bitterman PB, Polunovsky VA,. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 2003; 278: 3015-22.
36. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G,. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 2001; 20: 4041-9.
37. Matsushita K, Tomonaga T, Shimada H, Shioya A, Higashi M, Matsubara H, Harigaya K, Nomura F, Libutti D, Levens D, Ochiai T,. An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis. Cancer Res 2006; 66: 1409-17.
38. Khosla S,. Magic bullets to kill nasty osteoclasts. Endocrinology 2005; 146: 3233-4.